Is It Useful to Go Abroad After Multiple IVF Failures? A Reproductive Doctor Gives a Real Analysis

In the consultation room, a 40-year-old female patient sat before me, clutching three IVF treatment records. "Doctor, I've had three IVF cycles in China—two biochemical pregnancies and one complete implantation failure. I'm almost 41 now, and some people have suggested I try abroad. What do you think... Is it really useful to go abroad after multiple IVF failures?"

Why does the thought of "going abroad after multiple failures" arise?

Recurrent implantation failure (RIF) is one of the most challenging issues in assisted reproduction today. When patients experience two or more transfers of good-quality embryos without achieving clinical pregnancy in China, they naturally seek new possibilities. Asymmetrical overseas medical information, coupled with marketing emphasizing "third-generation IVF," "PGT-A," and "visa-free" concepts, can easily create an intuition that "foreign technology is more advanced and success rates are higher." However, from a clinical perspective, the key to judgment lies not in the "country" but in the specific cause of failure.

Is it useful to go abroad after multiple IVF failures? A direct answer

It has clear value under specific conditions, but it is not suitable for everyone. Foreign reproductive centers do have advantages in certain technical areas, such as:

• Preimplantation Genetic Testing for Aneuploidy (PGT-A) helps patients with recurrent embryonic aneuploidy leading to failure;
• Endometrial Receptivity Analysis (ERA) can identify a displaced window of implantation;
• Hysteroscopy and diagnosis of chronic endometritis are not routinely performed in some domestic institutions;
• Countries where egg or embryo donation is legally permitted can resolve the issue of egg source.

However, if the cause of failure is severe uterine malformation, autoimmune disease, uncontrolled thyroid dysfunction, or extremely high male DNA fragmentation, overseas protocols may not necessarily be effective. Therefore, whether to go abroad depends on what investigations you have already undergone to identify the cause of failure.

Case scenario analysis: Three typical situations

Situation 1: Advanced age, low AMH, recurrent embryonic chromosomal abnormalities

A 42-year-old woman with AMH 0.6 ng/mL. In China, she retrieved 3-4 eggs, and after blastocyst culture, only 1-2 were usable; transfer resulted in no implantation. If she goes to the US or Japan, she could utilize egg donation or mitochondrial replacement therapy (rarely used), or select chromosomally normal embryos through PGT-A. In such cases, overseas options can indeed offer technologies not legally available in China, but this depends on the patient's acceptance of donor eggs or having a sufficient budget.

Situation 2: Multiple transfers of good embryos without implantation, no hysteroscopy or endometrial microbiome testing done

A 35-year-old patient had two blastocyst transfers without implantation. In China, no hysteroscopy was performed; only ultrasound suggested uniform endometrial lining. At reproductive centers in Thailand or Spain, hysteroscopy + endometrial biopsy (CD138+ microbiome analysis) is routinely performed before transfer. Chronic endometritis was found, and after treatment, a subsequent transfer was successful. In this scenario, going abroad holds value.

Situation 3: Severe male oligoasthenospermia, but conventional ICSI is available in China

If the problem lies in a high sperm DNA fragmentation rate (>30%), most centers in China can perform testicular sperm aspiration, but sperm nuclear protein maturity testing is not routine. Some overseas laboratories offer sperm selection techniques (e.g., IMSI, PICSI) and dynamic sperm DFI testing. For such patients, going to Europe or Australia may be somewhat helpful.

Differences between countries: Technology, laws, and costs

Note: There are significant differences between hospitals within each country; decisions should not be based solely on the country. It is recommended to choose a center with technical advantages corresponding to your specific cause of failure.

The most easily overlooked details: Checklist for investigating failure causes

Many patients spend tens of thousands of dollars abroad, only to find that the cause of failure was chronic endometritis missed in domestic diagnosis. In such cases, treatment with antibiotics in China would suffice, and going abroad is entirely unnecessary.

Interpretation of key examination indicators: Helping you judge whether overseas is valuable

AMH and Antral Follicle Count

AMH < 1.0 ng/mL indicates severely diminished ovarian reserve. If you only retrieve 1-2 eggs per cycle in China, going abroad will not significantly increase the number of eggs retrieved. In this situation, the value of overseas lies in egg donation or mitochondrial activation (MitoQ), not in increasing your own follicle count.

FSH/LH Ratio

FSH > 10 IU/L with low LH suggests diminished ovarian function. Some overseas centers use growth hormone (GH) or DHEA pretreatment, but the evidence level is limited. This should be viewed rationally.

Endometrial Receptivity Analysis (ERA)

If ERA shows a displaced window of implantation (e.g., requiring transfer on P+6 day), many centers in China can now perform ERA, so going abroad is unnecessary. Only for rare window variants that cannot be detected in China (e.g., advancement to P+3 day) would it be necessary to go to a qualified laboratory abroad.

Embryonic Chromosomal Aneuploidy Rate

For women over 40, if previous embryo testing showed more than 70% aneuploidy, PGT-A can significantly improve the success rate per transfer. However, the cost of PGT-A in China is about 20,000-30,000 RMB, while overseas it is about 80,000-120,000 RMB; economic considerations are important.

Frequently asked questions

Practitioner's observation: Real changes over the past decade

I often encounter patients like this: after two failures in China, they go directly to Thailand for third-generation IVF, spend 200,000 RMB, and still have a biochemical pregnancy after transfer. Upon returning, they test positive for antiphospholipid antibodies and high NK cell cytotoxicity, and after immunotherapy, the third transfer is successful. There are also patients who cannot find a cause in China, go to the US for ERA, find a 1.5-day displacement of the implantation window, adjust medication, and succeed on the first try.

The truth is: "Multiple IVF failures" itself is not a reason to go abroad; the unidentified cause of failure is. Some reproductive centers in China, limited by cost or workflow, do not systematically investigate recurrent implantation failure. In contrast, some overseas clinics include PGT-A, ERA, and endometrial microbiome as routine packages, which can indeed help some patients. But if you haven't even had a hysteroscopy, going abroad first will likely lead you down the wrong path.

Doctor's advice

Note: This article does not constitute medical advice. Please discuss specific plans with your attending physician in person.